iShares Biotechnology ETF Rating $138.10 +0.83 (+0.60%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestTrendsBuy This Stock iShares Biotechnology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IBB Aggregate RatingModerate Buy 2.64Holdings in IBB have an aggregate rating of Moderate Buy based on 478 analyst ratings issued in the past year covering 25 companies (69.7% of the portfolio).IBB Aggregate Price Target$137.27-0.60% DownsideHigh Prediction$137.27Average Prediction$137.27Low Prediction$137.27Holdings in IBB have an aggregate price target of $137.27 and a range of $137.27 to $137.27 covering 25 companies (69.7% of the portfolio).IBB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy14 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares Biotechnology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 IBB Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.74%AMGNAmgen$293.26+1.0%4.6748 of 5 stars2.33$303.76 3.6%21Trending NewsAnalyst Revision7.73%VRTXVertex Pharmaceuticals$393.47+0.8%4.9451 of 5 stars2.56$497.10 26.3%27Positive News7.68%GILDGilead Sciences$118.72-0.3%4.8606 of 5 stars2.80$114.82 -3.3%25Positive NewsDividend AnnouncementAnalyst Revision6.51%REGNRegeneron Pharmaceuticals$580.72+2.6%4.8459 of 5 stars2.81$829.65 42.9%26Positive NewsDividend AnnouncementAnalyst ForecastAnalyst RevisionGap Up4.56%ALNYAlnylam Pharmaceuticals$439.25-0.8%4.2592 of 5 stars2.85$403.92 -8.0%27Positive News3.80%IQVIQVIA$191.09+0.9%4.9177 of 5 stars2.74$228.62 19.6%23Positive NewsShort Interest ↓Analyst Revision2.91%MTDMettler-Toledo International$1,316.43+0.2%4.016 of 5 stars2.50$1,288.89 -2.1%10Positive NewsInsider Trade2.53%ARGXargenex$647.36-0.8%3.8675 of 5 stars3.10$746.81 15.4%20Positive News2.14%BIIBBiogen$137.53+1.9%4.8712 of 5 stars2.34$185.74 35.1%32Analyst Forecast2.06%INSMInsmed$126.65-0.9%4.0352 of 5 stars2.94$129.57 2.3%16Trending NewsAnalyst ForecastAnalyst RevisionGap Up2.00%NTRANatera$159.14+0.4%3.2306 of 5 stars3.06$193.19 21.4%182.00%WATWaters$293.30-0.1%4.8065 of 5 stars2.47$378.73 29.1%151.92%BNTXBioNTech$113.06+0.3%1.7804 of 5 stars2.76$135.80 20.1%17Analyst Forecast1.87%ILMNIllumina$101.36+1.3%4.544 of 5 stars2.25$124.58 22.9%20Analyst Downgrade1.81%ONCBeOne Medicines$316.98+2.4%0.6726 of 5 stars3.00$330.89 4.4%7Gap Up1.49%INCYIncyte$86.09-0.1%4.5651 of 5 stars2.33$81.20 -5.7%181.49%UTHRUnited Therapeutics$313.01+0.3%4.9353 of 5 stars2.69$382.00 22.0%13Positive NewsAnalyst Forecast1.40%NBIXNeurocrine Biosciences$132.02+0.5%4.8677 of 5 stars2.86$160.90 21.9%22Positive News1.34%EXELExelixis$38.61+0.4%4.9099 of 5 stars2.55$44.06 14.1%22Positive NewsAnalyst Forecast1.30%MRNAModerna$27.91+4.6%4.4062 of 5 stars2.04$43.59 56.2%241.24%BMRNBioMarin Pharmaceutical$59.02+1.8%4.9979 of 5 stars2.75$93.17 57.9%24Positive News1.16%MEDPMedpace$460.66+0.4%4.3338 of 5 stars1.93$406.60 -11.7%14Positive News1.06%GMABGenmab A/S$23.42+1.9%3.989 of 5 stars2.64$37.60 60.5%111.01%TECHBio-Techne$54.12+0.7%4.9599 of 5 stars2.62$69.42 28.3%13Positive NewsDividend Announcement0.96%CRLCharles River Laboratories International$157.59+1.1%4.7924 of 5 stars2.27$175.69 11.5%15Positive News This page (NASDAQ:IBB) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access